<?php
// Register RankMath meta fields for REST API write access
// Required for publisher script to set focus keyword via REST API
add_action("init", function () {
foreach (
["rank_math_focus_keyword", "rank_math_title", "rank_math_description"]
as $key
) {
register_meta("post", $key, [
"show_in_rest" => true,
"single" => true,
"type" => "string",
"auth_callback" => function () {
return current_user_can("edit_posts");
},
]);
}
});

Untitled

by

— SEO TITLE: “AMC MCQ Cardiology: The Most Tested Topics and Patterns” META TITLE: “AMC MCQ Cardiology: The Most Tested Topics and Patterns | MplusX” META DESCRIPTION: “Comprehensive guide on cardiology AMC MCQ topics for international medical graduates preparing for the AMC MCQ exam.” URL SLUG: “cardiology-amc-mcq-topics” TARGET KEYWORD: “cardiology AMC MCQ topics” CONTENT PILLAR: “P4” SEARCH INTENT: “Info” FUNNEL STAGE: “TOFU” GOAL: “Authority”

AMC MCQ Cardiology: Most Tested Topics and Patterns (2026)

Last reviewed: May 2026 | Written by the MplusX Editorial Team

📌 Key Takeaways

  • ACS Triage: Emergency management of acute coronary syndrome requires a strict triage sequence: perform a 12-lead ECG within 10 minutes, administer chewable Aspirin 300mg, and evaluate for immediate reperfusion (PCI vs. Thrombolysis).
– Heart Failure Four Pillars: Modern management of Heart Failure with Reduced Ejection Fraction (HFrEF) is built around four mandatory drug classes: ACEi/ARNI, beta-blocker, MRA, and SGLT2i.
– Atrial Fibrillation Score: Under Australian guidelines, use the CHA2DS2-VA score (which excludes the female gender score) to guide oral anticoagulation decisions.
– Primary CTA: Read the General Medicine High-Yield Guide — a comprehensive resource detailing eTG prescribing guidelines and clinical pathways across all major medical specialties.

A 58-year-old male walks into your clinic clutching his chest, sweating profusely, and struggling to breathe.

Your immediate next step is not to wait for troponin results or order a chest X-ray—you must perform a 12-lead ECG within 10 minutes and administer 300mg of chewable aspirin.

Cardiology questions on the AMC MCQ are highly clinical and safety-driven. The examiners assess whether you can distinguish acute, life-threatening events from stable, chronic diseases.

In Australia, these pathways conform strictly to Therapeutic Guidelines (eTG) and National Heart Foundation protocols.

Selecting an incorrect drug dose, mismanaging anticoagulation timelines, or failing to identify absolute contraindications represents an immediate exam failure.

1. Acute Coronary Syndrome (ACS): The Emergency Triage Sequence

When a patient presents with acute chest pain, the primary exam priority is identifying or excluding a ST-Elevation Myocardial Infarction (STEMI). The triage sequence must be executed systematically:

graph TD

A[“Patient Presents with Acute Chest Pain”] –> B[“Perform 12-Lead ECG within 10 Minutes”]

B –> C{“STEMI Documented on ECG?”}

C –>|Yes| D[“Administer Chewable Aspirin 300mg + Call Ambulance”]

D –> E{“On-site PCI available within 120 mins?”}

E –>|Yes| F[“Urgent Transfer for Primary PCI”]

E –>|No| G[“Perform Immediate Fibrinolysis / Thrombolysis unless contraindicated”]

C –>|No| H[“Check Troponin levels & assess for NSTEMI / UAP”]

style A fill:#0F2D5C,stroke:#fff,color:#fff

style B fill:#D69E2E,stroke:#fff,color:#fff

style D fill:#991B1B,stroke:#fff,color:#fff

style F fill:#166534,stroke:#fff,color:#fff

High-Yield Emergency Steps to Memorize

1. Perform ECG Immediately

Order a 12-lead ECG within 10 minutes of presentation. Do not wait for troponin results to triage chest pain.

2. Aspirin First

If ACS is clinically suspected, immediately administer aspirin 300mg orally, chewed. Chewing ensures rapid systemic antiplatelet activity.

3. Oxygen Triage

Do not administer oxygen routinely. Under Australian thoracic guidelines, only administer oxygen if the patient’s oxygen saturation is below 93% (or below 88-92% in patients with documented COPD). Routine oxygen therapy in normoxaemic patients causes coronary vasoconstriction and increases myocardial injury.

4. Reperfusion Decisions (PCI vs. Lysis)

* If the patient is at a hospital with PCI capabilities (or can be transferred to one within 120 minutes of first medical contact), the correct choice is Primary Percutaneous Coronary Intervention (PCI). * If transfer to a PCI-capable hospital will take more than 120 minutes, the correct choice is immediate fibrinolysis (thrombolysis) on-site, provided there are no absolute contraindications (e.g. recent hemorrhagic stroke, active bleeding, or suspected aortic dissection).

NSTEMI vs. Unstable Angina Triage and Risk Stratification

If the 12-lead ECG does not show ST-elevation, but the patient has suggestive clinical history, they are triaged under the NSTEMI/Unstable Angina (UA) pathway:

Diagnostic Distinction:* NSTEMI is characterized by elevated cardiac biomarkers (Troponin I or T) showing myocardial necrosis, whereas Unstable Angina presents with normal biomarkers but clinical chest pain at rest or with minimal exertion.

Risk Stratification:* In Australia, patients with suspected non-ST-elevation acute coronary syndromes (NSTE-ACS) are risk-stratified using clinical parameters (e.g. GRACE risk score or TIMI score) to guide the timing of invasive angiography:

High-Risk Features (Invasive within 24 hours):* Ongoing chest pain refractory to medical treatment, dynamic ST-segment changes (ST-depression >=0.5mm or transient elevation), hemodynamic instability (hypotension, cardiogenic shock), or life-threatening ventricular arrhythmias. The correct management is immediate therapeutic heparin (unfractionated or LMWH like enoxaparin), dual antiplatelet therapy (DAPT), and urgent coronary angiography.

Intermediate-to-Low Risk (Invasive within 72 hours or conservative outpatient):* Stable symptoms with no dynamic ECG changes and negative/mildly elevated troponins. Manage medically with DAPT and plan elective outpatient angiography or non-invasive ischemia testing.

2. Heart Failure: The Active eTG “Four Pillars” of HFrEF

Management of chronic Heart Failure with Reduced Ejection Fraction (HFrEF, EF <40%) has evolved. The eTG defines four mandatory drug classes (the “Four Pillars”) that must be initiated to reduce mortality:

1. ACE Inhibitor (ACEi) OR Angiotensin Receptor-Neprilysin Inhibitor (ARNI):

Drug:* Ramipril or Sacubitril/Valsartan.

Dosing Rule: Start low and titrate upward. ARNI is preferred over ACEi in patients who remain symptomatic despite optimal ACEi therapy. Safety rule: You must allow a strict 36-hour washout period when switching from an ACEi to an ARNI to prevent severe angioedema.*

2. Beta-blocker:

Drug:* Bisoprolol, Carvedilol, or Metoprolol Succinate.

Prescribing Rule:* Initiate only when the patient is stable and euvolemic. Do not initiate or increase beta-blocker doses during an acute decompenstated heart failure flare (which presents with fluid overload/pulmonary congestion), as this will worsen cardiogenic shock.

3. Mineralocorticoid Receptor Antagonist (MRA):

Drug:* Spironolactone or Eplerenone.

Monitoring:* Check renal function (eGFR) and potassium weekly during initiation. Discontinue if potassium exceeds 5.5 mmol/L.

4. SGLT2 Inhibitor (SGLT2i):

Drug:* Empagliflozin or Dapagliflozin.

Indication:* Indicated for all HFrEF patients, regardless of whether they have type 2 diabetes, to reduce hospitalization rates.

3. Atrial Fibrillation: Rate vs. Rhythm and the CHA2DS2-VA Score

Atrial Fibrillation (AF) questions evaluate your ability to manage rate control, rhythm restoration, and systemic thromboembolic stroke prevention.

Rate vs. Rhythm Triage

* Hemodynamically Unstable: If the patient is unstable (hypotension, acute pulmonary edema, chest pain) due to rapid AF, the correct answer is immediate emergency direct current (DC) cardioversion. * Hemodynamically Stable: The first-line goal is rate control using a beta-blocker (metoprolol) or non-dihydropyridine calcium channel blocker (diltiazem/verapamil).

Anticoagulation: The CHA2DS2-VA Score

To determine if a patient with stable AF requires oral anticoagulation, use the CHA2DS2-VA tool.

Critical Exam Pearl: Under the current Australian guidelines, the female gender category (Sc) is excluded from the score calculation, as female gender alone does not increase stroke risk in the absence of other risk factors. This differs from the European/US CHA2DS2-VASc score.

Use this scoring table to guide your exam choices:

Risk FactorDefinitionPoints
CCongestive Heart Failure (or LVEF <=40%)1
HHypertension1
AAge >=75 years2
DDiabetes mellitus1
SStroke / TIA / Thromboembolism history2
VVascular disease (prior MI, PAD, aortic plaque)1
AAge 65 to 74 years1

Management Rules based on Score:

* Score = 0: Oral anticoagulation is not recommended. * Score = 1: Consider oral anticoagulation (clinical judgment). * Score >= 2: Oral anticoagulation is strongly recommended (first-line is a DOAC like Apixaban or Rivaroxaban; Warfarin is reserved for mechanical valves or moderate-to-severe mitral stenosis).

Anticoagulation Timing Rules for Cardioversion

When planning rhythm control via electrical or pharmacological cardioversion in a stable patient with atrial fibrillation, you must strictly follow the anticoagulation timing rules:

* AF Duration < 48 Hours:

Management:* If you can verify that the onset of AF is strictly less than 48 hours ago, cardioversion can be performed safely without pre-cardioversion anticoagulation, as the risk of atrial thrombus formation is low.

Post-cardioversion: Administer therapeutic anticoagulation (LMWH or DOAC) prior* to or immediately after cardioversion. Continue oral anticoagulation for at least 4 weeks post-cardioversion, regardless of the patient’s baseline CHA2DS2-VA score, because the left atrium remains stunned and thrombus can form during recovery.

* AF Duration >= 48 Hours (or Unknown Onset):

Management:* Cardioversion must not be attempted immediately due to the high risk of dislodging an atrial thrombus, leading to ischemic stroke.

Anticoagulation Rule:* The patient must be therapeutically anticoagulated with a DOAC or Warfarin for at least 3 consecutive weeks before cardioversion is attempted.

Alternative (Transoesophageal Echocardiogram [TOE] pathway):* If cardioversion is preferred earlier, you can perform a TOE to directly exclude the presence of a left atrial appendage thrombus. If TOE is clear of thrombus, cardioversion can be performed immediately, provided the patient is therapeutically anticoagulated (e.g. IV heparin/LMWH) during the procedure.

Post-cardioversion:* Maintain oral anticoagulation for at least 4 weeks post-cardioversion, followed by long-term anticoagulation based on their CHA2DS2-VA score.

4. Hypertension: The 2026 AusCVDRisk Guidelines

In Australia, the initiation of antihypertensive therapy is not determined solely by blood pressure numbers (unless BP is severe, >180/110 mmHg). Instead, it is guided by the patient’s absolute cardiovascular disease (CVD) risk, calculated using the AusCVDRisk portal (updated in late 2023/2026 guidelines).

The AusCVDRisk tool estimates the probability of a cardiovascular event occurring over the next 5 years, categorizing patients into three risk bands:

1. Low Risk (<5%): First-line is lifestyle modification (diet, exercise, smoking cessation). Reassess in 2 years. Do not start medication.

2. Intermediate Risk (5% to 9%): Lifestyle modification. Consider antihypertensive medication if blood pressure remains >140/90 mmHg after 3-6 months.

3. High Risk (>=10%): Initiate pharmacological therapy immediately (antihypertensives + statin), regardless of the baseline blood pressure, to achieve protective cardiovascular benefits.

High-Risk Defaults (No calculation needed): On the exam, some patients are automatically classified as high risk without needing a calculator. These include patients with:

* Established cardiovascular disease (prior MI, stroke, peripheral vascular disease). * Moderate-to-severe Chronic Kidney Disease (eGFR <30 mL/min or macroalbuminuria). * Familial Hypercholesterolaemia. * Age >75 years with diabetes.

5. Infective Endocarditis: Duke Criteria and Dental Prophylaxis

Infective Endocarditis (IE) is a critical topic testing diagnostic criteria and preventative prescribing.

Diagnostic Criteria: The Modified Duke Criteria

To establish a diagnosis of infective endocarditis, the patient must meet the Modified Duke Criteria (2 major, 1 major + 3 minor, or 5 minor criteria):

Major Criteria:*

1. Positive blood cultures for typical IE microorganisms (e.g., Staphylococcus aureus, Streptococcus viridans, Enterococci) from at least 2 separate blood cultures.

2. Evidence of endocardial involvement on echocardiography (oscillating intracardiac mass/vegetation, abscess, new valvular regurgitation, or prosthetic valve dehiscence).

Minor Criteria:*

1. Predisposition (heart condition or IV drug use).

2. Fever >= 38.0°C.

3. Vascular phenomena (arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages, Janeway lesions).

4. Immunological phenomena (glomerulonephritis, Osler’s nodes, Roth spots, rheumatoid factor).

5. Microbiological evidence (positive blood culture that does not meet a major criterion).

Dental Prophylaxis Guidelines (2026 eTG)

Under Australian guidelines, routine antibiotic prophylaxis for dental procedures is not recommended for the vast majority of patients with cardiac lesions to prevent endocarditis. It is reserved only for patients with high-risk cardiac conditions undergoing high-risk dental procedures (procedures involving manipulation of the gingival tissue, periapical region of teeth, or perforation of the oral mucosa).

High-Risk Cardiac Conditions:*

1. Prosthetic heart valve or prosthetic material used for valve repair.

2. History of previous infective endocarditis.

3. Congenital heart disease (CHD) but only if it is:

* Unrepaired cyanotic CHD (including palliative shunts and conduits). * Completely repaired CHD with prosthetic material during the first 6 months post-procedure. * Repaired CHD with residual defects at the site of a prosthetic patch or device.

4. Rheumatic heart disease in high-risk patients (Indigenous Australians from remote communities, patients with severe valvular dysfunction).

Antibiotic Prophylaxis Dosing (Oral):*

First-line:* Amoxicillin 2g orally, administered 1 hour prior to the dental procedure (Pediatric dose: 50 mg/kg up to 2g).

Hypersensitivity to Penicillin (non-severe/delayed):* Cephalexin 2g orally (Pediatric: 50 mg/kg).

Severe immediate hypersensitivity to Penicillin (anaphylaxis):* Clindamycin 600mg orally (Pediatric: 20 mg/kg up to 600mg) or Azithromycin 500mg orally (Pediatric: 15 mg/kg up to 500mg).

Frequently Asked Questions

What is the first-line antihypertensive drug class for pregnant patients?

On the AMC MCQ, standard antihypertensives like ACE inhibitors (ramipril) and ARBs (candesartan) are strictly contraindicated in pregnancy due to fetal renal dysgenesis and toxicity. The correct first-line options for managing gestational hypertension or pre-eclampsia are: oral methyldopa, oral labetalol, or oral nifedipine.

When is rhythm control preferred over rate control in stable AF?

Rhythm control (using pharmacologic agents like amiodarone, flecainide, or catheter ablation) is preferred in stable patients who:

* Remain symptomatic despite optimal rate control. * Are young and active (<65 years). * Have tachycardia-induced cardiomyopathy. * Are presenting with their first-ever episode of AF.

What is the maximum dose of Atropine in bradycardia?

Under ALS guidelines, for symptomatic bradycardia, administer atropine 500 mcg IV every 3 to 5 minutes, up to a maximum total dose of 3 mg (6 doses). If bradycardia is refractory to atropine, the next step is transcutaneous pacing or an isoprenaline infusion.

What are the contraindications for SGLT2 inhibitors in heart failure?

SGLT2 inhibitors (dapagliflozin, empagliflozin) should not be initiated if the patient’s estimated glomerular filtration rate (eGFR) is below 20-30 mL/min/1.73m² (depending on the specific drug license). They are also contraindicated in patients with a history of recurrent diabetic ketoacidosis (DKA) or active diabetic foot ulcers.

How is absolute CVD risk calculated in patients with type 1 diabetes?

Patients with Type 1 Diabetes aged over 35 years are automatically classified as high absolute cardiovascular risk under Australian guidelines if they have microalbuminuria or other microvascular complications. They do not require calculation using the standard AusCVDRisk tool; initiate statin and antihypertensive therapy if indicated.

Why do we withhold beta-blockers in acute heart failure flares?

Beta-blockers are negative inotropes. In acute decompensated heart failure (fluid overload, pulmonary congestion, or cardiogenic shock), the heart is relying on sympathetic drive to maintain cardiac output. Initiating or increasing a beta-blocker in this acute phase will suppress contractility, causing immediate hemodynamic collapse. You must stabilize the patient with loop diuretics (IV frusemide) first.

How do you differentiate acute pericarditis from a STEMI on an ECG?

Acute pericarditis and ST-elevation myocardial infarction (STEMI) both present with chest pain and ST-segment elevation, but their ECG patterns are distinct:

Pericarditis:* Characterized by widespread, diffuse concave ST-elevation (saddle-shaped) across multiple vascular territories, accompanied by PR-segment depression (highly specific, especially in leads II, aVF, and V2-V6) and reciprocal PR-elevation in lead aVR. Reciprocal ST-depression is absent except in leads aVR and V1.

STEMI:* Characterized by localized convex ST-elevation matching a specific coronary arterial distribution (e.g. leads II, III, aVF for inferior wall RCA occlusion; leads V1-V4 for anterior wall LAD occlusion), showing reciprocal ST-segment depression in opposing leads. PR-segment changes do not occur, and pathological Q-waves may evolve.

Written by the MplusX Editorial Team — dedicated to providing clinically accurate, structured, and practical resources for international medical graduates pursuing licensing with the Australian Medical Council.

References

  • John Murtagh’s General Practice (8th Edition): Chapter 30: Chest pain; Chapter 59: Palpitations; Chapter 75: Cardiovascular disease; Chapter 76: Chronic heart failure.
  • RACGP Red Book (10th edition): Chapter 8: Prevention of vascular and metabolic disease.
  • Therapeutic Guidelines (eTG): Part 2 Cardiovascular: Acute coronary syndromes, Heart failure.

Disclaimer: This article is written for AMC MCQ examination preparation and general informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Clinical decisions should always be based on individual patient assessment, current Australian Therapeutic Guidelines (eTG), and consultation with qualified healthcare professionals. MplusX is an exam preparation platform and is not a substitute for supervised clinical training.

Leave a Comment